Defunct Company
Total Trials
82
As Lead Sponsor
73
As Collaborator
9
Total Enrollment
9,892
NCT01040780
Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients
Phase: Phase 3
Role: Lead Sponsor
Start: Feb 28, 2009
Completion: Dec 31, 2011
NCT02544789
Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Phase: Phase 2
Start: Jun 30, 2009
Completion: May 31, 2012
NCT02486354
Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
Start: Mar 31, 2010
Completion: Apr 30, 2012
NCT01465243
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
Phase: Phase 4
Start: Sep 30, 2011
Completion: Feb 28, 2014
NCT01516983
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
Phase: Phase 1/2
Start: Dec 31, 2011
Completion: Dec 31, 2013
NCT01646450
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
Start: Jul 31, 2012
Completion: Apr 30, 2016
NCT01665417
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Start: Aug 31, 2012
Completion: Dec 31, 2017
NCT01690390
Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease
Start: Sep 30, 2012
Completion: Jul 31, 2016
NCT01707329
Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
Completion: Dec 31, 2016
NCT01719536
Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients
Start: Dec 31, 2012
Completion: Feb 7, 2017
NCT01720901
Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy
Start: Feb 28, 2013
NCT01843647
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
Start: Apr 30, 2013
Completion: Feb 28, 2018
NCT01855854
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
Start: May 31, 2013
Completion: Jan 7, 2016
NCT01926171
Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
Start: Jun 30, 2013
NCT01929200
Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
Start: Aug 31, 2013
Completion: Aug 31, 2017
NCT02024633
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Phase: Phase 1
Start: Dec 31, 2013
Completion: Mar 31, 2016
NCT02027090
High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease
Start: Jan 31, 2014
NCT02044328
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
Completion: Oct 31, 2021
NCT02066870
Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
Completion: Jan 31, 2016
NCT02062515
Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
Start: Feb 28, 2014
Completion: Jun 30, 2016
NCT02103257
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Start: Mar 31, 2014
Completion: Sep 30, 2017
NCT02194556
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
Start: Jul 31, 2014
Completion: Jul 31, 2017
NCT02215356
Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
Start: Aug 31, 2014
Completion: Feb 28, 2019
NCT02125240
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
Start: Sep 30, 2014
Completion: Jul 31, 2021
NCT02278458
Start: Oct 31, 2014
Completion: Oct 31, 2016
NCT02328261
A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
Start: Nov 30, 2014
Completion: Apr 30, 2017
NCT02404675
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
Start: Apr 30, 2015
Completion: Sep 30, 2018
NCT02448797
Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation
Start: Jun 8, 2015
Completion: Dec 31, 2023
NCT02478866
Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors
Start: Aug 11, 2015
Completion: Nov 30, 2017
NCT02574091
Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients
Start: Nov 26, 2015
Completion: Feb 19, 2017
NCT02726568
High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
Start: Mar 31, 2016
Completion: Dec 31, 2022
NCT02934256
Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Role: Collaborator
Start: Jul 31, 2016
Completion: Jul 31, 2018
NCT02801435
Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
Start: Sep 17, 2016
Completion: Jun 8, 2017
NCT02914990
Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients
Start: Dec 29, 2016
Completion: Mar 7, 2019
NCT02929290
Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC
Start: Mar 1, 2017
Completion: Nov 30, 2024
NCT02959619
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
Start: Mar 6, 2017
Completion: Apr 23, 2020
NCT03188848
Dose Escalating Study of BPI-3016 in Healthy Subjects
Start: May 24, 2017
Completion: Dec 31, 2019
NCT03196986
mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer
Start: Aug 15, 2017
Completion: Jul 30, 2021
NCT03215693
X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
Start: Sep 28, 2017
NCT03346811
Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer
Start: Nov 18, 2017
Completion: Mar 10, 2020
NCT03222622
Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
Start: Nov 29, 2017
Completion: Oct 26, 2018
NCT03402464
Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC
Start: Jan 31, 2018
Completion: Sep 20, 2020
NCT03510611
A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.
Start: Mar 12, 2018
Completion: Aug 2, 2018
NCT03396185
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer
Start: May 9, 2018
Completion: Feb 1, 2023
NCT03536481
Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers
Start: Jun 11, 2018
Completion: Jan 9, 2019
NCT03608007
X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement
Start: Jun 15, 2018
Completion: Sep 30, 2020
NCT04058704
A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy
Start: Jul 20, 2018
NCT03349203
Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer
Start: Oct 1, 2018
Completion: Dec 30, 2023
NCT03749213
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer
Start: Dec 1, 2018
Completion: Dec 30, 2024
NCT03754530
Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
Completion: Dec 1, 2021
NCT03804541
The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human
Start: Dec 28, 2018
Completion: Oct 31, 2019
NCT04415320
X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Start: Mar 21, 2019
Completion: Jun 30, 2021
NCT03753685
X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Start: Apr 12, 2019
Completion: Jun 30, 2026
NCT03791112
A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor
Start: Jul 18, 2019
Completion: Dec 31, 2025
NCT04206072
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
Phase: Phase 2/3
Start: Dec 24, 2019
Completion: Jul 15, 2025
NCT04464551
The Absorption, Metabolism and Excretion of [14C]D-0316 in Human
Start: Dec 5, 2020
Completion: Aug 31, 2021
NCT05302843
A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors
Start: Mar 22, 2021
NCT04946890
A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Start: Jul 1, 2021
Completion: Dec 31, 2024
NCT05329298
A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors
Start: Jul 21, 2021
NCT05007938
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
Start: Aug 12, 2021
NCT05315180
A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
Start: Aug 24, 2021
Completion: Jul 31, 2023
NCT04930432
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Start: Sep 24, 2021
Completion: Dec 30, 2028
NCT05033132
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
Start: Oct 1, 2021
NCT05132218
Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Phase: N/A
Start: Oct 19, 2021
Completion: Oct 30, 2024
NCT05186506
A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer
Start: Jan 1, 2022
Completion: Dec 20, 2028
NCT05341570
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668
Start: Jan 19, 2022
Completion: Jan 31, 2025
NCT05316259
A Food-Effect Study of BPI-16350 in Healthy Subjects
Start: Apr 15, 2022
Completion: Aug 30, 2022
NCT05498064
A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
Start: May 13, 2022
Completion: Dec 1, 2028
NCT05341583
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Start: May 24, 2022
Completion: Jul 23, 2025
NCT05433480
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
Start: May 25, 2022
Completion: Jul 31, 2025
NCT05369312
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
Start: Jun 30, 2022
Completion: May 1, 2025
NCT05341557
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Start: Aug 29, 2022
Completion: Apr 30, 2027
NCT06041776
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Start: Mar 28, 2023
Completion: Nov 30, 2029
NCT05789602
A Study of BPI-460372 in Advanced Solid Tumor Patients
Start: Apr 24, 2023
Completion: Apr 17, 2026
NCT05843305
A Study of BPI-452080 in Subjects With Solid Tumors
Start: Apr 28, 2023
Completion: Oct 31, 2025
NCT05869240
BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors
Start: May 16, 2023
Completion: Sep 1, 2025
NCT06015568
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
Start: Sep 1, 2023
Completion: Jul 4, 2029
NCT06492525
A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers
Start: Jul 31, 2024
NCT06641609
A Phase I Study of CFT8919 in Patients With Advanced NSCLC
Start: Dec 13, 2024
Completion: Apr 3, 2026
NCT06780839
Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
Start: Jan 15, 2025
Completion: Jan 15, 2030
NCT06885840
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
Start: Mar 31, 2025
Completion: Sep 30, 2028
NCT07181499
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Start: Sep 30, 2025
Completion: Dec 31, 2028